Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ImmunoScape","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valo Therapeutics and ImmunoScape Collaboration Identifies Immunogenic Peptides to Develop Pan Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"SINGAPORE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Pure MHC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoScape Inks Licensing Deal with Pure MHC to Advance Development of Novel TCR-Based Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Anzu Partners","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Experimental Drug Development Centre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ImmunoScape Partners with Singapore\u2019s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by ImmunoScape

    Menu

    ImmunoScape

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ImmunoScape

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics

              Details:

              Through the partnership, EDDC will apply its expertise in therapeutic protein design and antibody engineering to develop these novel TCR-based bispecific molecules for the treatments for solid tumors.

              Lead Product(s): TCR-based Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Experimental Drug Development Centre

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership December 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmunoScape

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-cell Receptors

              Details:

              ImmunoScape’s Deep Immunomics and machine learning platforms comprise a highly effective method for the discovery of T-cell receptor (TCR) candidates, targeting novel antigens such as cancer-specific shared splice variants and human endogenous retroviral elements.

              Lead Product(s): TCR-T-cell Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Anzu Partners

              Deal Size: $14.0 million Upfront Cash: Undisclosed

              Deal Type: Financing September 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmunoScape

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ImmunoScape Inks Licensing Deal with Pure MHC to Advance Development of Novel TCR-Based Therapies

              Details:

              The licensing deal will allow ImmunoScape to pursue TCR-T therapeutics using this library, and accelerate identification of novel T cell receptors for therapeutic development.

              Lead Product(s): TCR-T Therapeutics

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Pure MHC

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement February 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ImmunoScape

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Singapore
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Valo Therapeutics and ImmunoScape Collaboration Identifies Immunogenic Peptides to Develop Pan Coronavirus Vaccine

              Details:

              Valo Tx, will use its proprietary PeptiVAX technology to coat a spike-expressing adenoviral vector vaccine with HLA-restricted peptides. These peptides may be associated with a clinically beneficial T cell immune responses to Sars-CoV-2's highly conserved genes.

              Lead Product(s): Peptide based-pan Coronavirus vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Valo Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY